as on September 17, 2025 at 1:29 am IST
Day's Low
Day's High
0.71%
Downside
0.63%
Upside
52 Week's Low
52 Week's High
44.63%
Downside
2.27%
Upside
Check Halozyme Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$9.0B
EPS (TTM)
6.0528
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.85%
PE Ratio (TTM)
17.59
Industry PE ratio
10.127857142857144
P/B Ratio
17.5876
PEG Ratio
-2.5
EBITDA
758.6M
Revenue (TTM)
1.2B
Profit Margin
47.28%
Return On Equity TTM
179.14%
Track how Halozyme Therapeutics, Inc. P/E has moved over time to understand its valuation trends.
Halozyme Therapeutics, Inc. in the last 5 years
Lowest (10.98x)
June 30, 2025
Industry (10.13x)
September 16, 2025
Today (17.59x)
September 16, 2025
Highest (174.04x)
September 30, 2020
Today’s Price to Earnings Ratio: 17.59x
Compare market cap, revenue, PE, and other key metrics of Halozyme Therapeutics, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $9.0B | 173% | 17.59 | 47.28% | |
BUY | $61.1B | 251.26% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $101.2B | 47.46% | 28.09 | 31.86% | |
BUY | $59.6B | 0.6% | 14.1 | 31.37% |
The Halozyme Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Halozyme Therapeutics, Inc. investment value today
Current value as on today
₹1,25,468
Returns
₹25,468
(+25.47%)
Returns from Halozyme Therapeutics, Inc. Stock
₹20,601 (+20.6%)
Dollar Returns*
₹4,867 (+4.87%)
Based on 17 analysts
82.35%
Buy
17.65%
Hold
0.00%
Sell
Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Halozyme Therapeutics, Inc.. Average target price of $70.56
Get share price movements and forecasts by analysts on Halozyme Therapeutics, Inc..
What analysts predicted
-7.53%DOWNSIDE
Target Price
$70.56
Current Price
$75.87
Analyzed by
17 Analysts
Target
$70.56
Halozyme Therapeutics, Inc. target price $70.56, a slight downside of -7.53% compared to current price of $75.87. According to 17 analysts rating.
Search interest for Halozyme Therapeutics, Inc. Stock has increased by 90% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:90% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Revenue is up for the last 2 quarters, 264.86M → 325.71M (in $), with an average increase of 18.7% per quarter
Price Rise
In the last 1 month, HALO stock has moved up by 13.5%
Profit Spike
Netprofit is up for the last 2 quarters, 118.09M → 165.16M (in $), with an average increase of 28.5% per quarter
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 29.6%
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.2% return, outperforming this stock by 44.9%
Organisation | Halozyme Therapeutics, Inc. |
Headquarters | 12390 El Camino Real, San Diego, CA, United States, 92130 |
Industry | Health Technology |
CEO | Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Ms. Tram Bui | Head of Investor Relations & Corporate Communications |
Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer |
Mr. Paul Spence | Chief Commercial Officer |
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director |
Mr. Mark Snyder Esq. | Senior VP, General Counsel, Chief Compliance Officer & nd Secretary |
Ms. Amy Marinne Fox | Chief Human Resources Officer |
Dr. Christopher Wahl M.B.A., M.D. | Chief Business Officer |
Ms. Nicole LaBrosse CPA | Senior VP & CFO |
Ms. Cortney Caudill M.B.A. | Chief Operations Officer |
Halozyme Therapeutics, Inc. share price today is $75.87 as on at the close of the market. Halozyme Therapeutics, Inc. share today touched a day high of $76.35 and a low of $75.33.
Halozyme Therapeutics, Inc. share touched a 52 week high of $77.6 on and a 52 week low of $42.01 on . Halozyme Therapeutics, Inc. stock price today i.e. is closed at $75.87,which is 2.22% down from its 52 week high and 80.60% up from its 52 week low.
Halozyme Therapeutics, Inc. market capitalisation is $0.01T as on .
Indian investors can start investing in Halozyme Therapeutics, Inc. (HALO) shares with as little as ₹88.042 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹880.42 in Halozyme Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Halozyme Therapeutics, Inc. share’s latest price of $75.87 as on September 17, 2025 at 1:29 am IST, you will get 0.1318 shares of Halozyme Therapeutics, Inc.. Learn more about
fractional shares .
Halozyme Therapeutics, Inc. stock has given 173% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?